[Skip to Content]
[Skip to Content Landing]
Views 1,201
Citations 0
Research Letter
March 2017

Discontinuation of Warfarin Therapy for Patients With Atrial FibrillationThe Michigan Anticoagulation Quality Improvement Initiative Experience

Author Affiliations
  • 1Frankel Cardiovascular Center, University of Michigan Health System, Ann Arbor
  • 2Henry Ford Hospital, Detroit, Michigan
  • 3Huron Valley Sinai-Cardiology and Vascular Associates, Commerce Township, Michigan
JAMA Cardiol. 2017;2(3):341-343. doi:10.1001/jamacardio.2016.5041

The use of warfarin significantly reduces the risk of stroke among patients with atrial fibrillation (AF). Unfortunately, up to 60% of patients discontinue therapy within the first year.1 Prior studies did not assess the quality of warfarin therapy or the occurrence of electrical cardioversion (ECV) or radiofrequency ablation (RFA) as predictors of discontinuation of warfarin therapy.

First Page Preview View Large
First page PDF preview
First page PDF preview
×